anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a method for inducing a CTL (cytotoxic T lymphocyte) usable for treatment, etc., of intractable diseases such as cancer or viral infectious diseases and functioning specifically to disease antigens.  &lt;P&gt;SOLUTION: The method for inducing the CTL is carried out as follows. A cell line expressing at least MHC (major histocompatibility complex) class I and an co-stimulatory molecule is co-cultured with a lymphocyte after or while being brought into contact with a disease antigenic peptide. The CTL induced by the method is useful for, e.g. a drug for the cancer or infectious diseases and a therapeutic/prophylactic method therefor. A latent proliferation ability of the CTL can be tested according to the method for induction.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
PURPOSE:To provide a vaginal suppository having good absorbability on mucosa, especially vaginal mucosa, not having a mucosa-irritating property, having excellent stability and useful for treating endometriosis by containing danazol and a polyoxyethylene alkyl ether. CONSTITUTION:A suppository contains 1 pt.wt. of danazol and 0.1-20 pts.wt. preferably 0.2-5 pts.wt. of a polyoxyethylene alkyl ether, preferably polyoxyethylene stearyl ether or polyoxyethylene oleyl ether addition-reacted with &gt;=15 moles of ethylene oxide. The suppository is further compounded with a molding agent such as cacao fat, hard fat, laurin fat, glycerol monopalmitate or glycerogelatin and a viscosity-adjusting agent such as glycerol, polyoxyethylene glycol having an average mol.wt. of &lt;=600, propylene glycol or medium chain fatty acid triglyceride.
From diagnostic imaging to drug delivery, nanoparticles have found a tremendous variety of uses across fields. Often, when designing these nanoscale constructs, the two most important criteria are particle size and core loading. For example, small particles below 100nm can have many advantages for drug delivery - including improved specificity to tumors through the enhanced permeability and retention (EPR) effect. Likewise, higher loading nanoparticles translate very well to more effective drug delivery and cancer imaging- allowing for lower dosage and reduced costs. Traditional formulations of nanoparticles using drug absorption or precipitation methods generally struggle to obtain &gt;50% loading. Disclosed herein is a precipitation process allowing for production of stable particles at very high core loading by taking advantage of different time scales while maintaining biologically relevant sizes. New mixing designs allow for the separation of the precipitation and stabilization steps to generate these high loading nanoparticles.
PURPOSE:To obtain an oral cavity lubricant having improved wettability and lubricity and capable of sufficiently mitigating the disagreeable feeling and pain, etc., in the fitting of denture, by using a water-soluble or water-swelling organic polymeric compound of non-animal origin in combination with a surfactant, thereby adjusting the surface tension and viscosity of the lubricant to respective specific levels. CONSTITUTION:A water-soluble or water-swelling organic polymeric compound of non-animal origin, e.g. carboxymethylcellulose is used as a lubricating component of an oral cavity lubricant to impart lubricity to oral cavity by spraying or application and to mitigate the disagreeable feeling and pain, etc., of oral cavity in attaching a denture or prosthesis to oral cavity. In combination with the above lubricant, a surfactant approved as a food additive, e.g. sucrose fatty acid ester, etc., is compounded to the agent to adjust the surface tension to 10-60dyne/cm&lt;2&gt; and the viscosity to 2-100cps. The compatibility (wettability, lubricity, etc.) to oral cavity and denture, etc., can be improved and the disagreeable feeling and pain of oral cavity can be sufficiently suppressed or eliminated in the objective oral cavity lubricant.
Injectable medicament formulations comprise a water/oil emulsion suspended in a biologically acceptable aq. soln. The vol. ratio of the soln. phase to the emulsion phase is &gt;=1:2. The external phase of the emulsion comprises an oil which will be transported through the body, and an oil-sol. surfactant. The internal phase comprises a medicament which will be released into the body fluids over a predetermined period of time. The formulations have a lower viscosity than conventional emulsions; injections are thus less painful.
Protein antigens are provided. The protein antigens typically include a peptide antigen conjugated or fused to a chaperone protein to form a &#34;chaperone-antigen&#34; that increases lymph node uptake; improves an immune response; or a combination thereof relative to the peptide antigen alone. The immune response can be, for example, increased antigen-specific proliferation, enhanced cytokine production, stimulation of differentiation and/or effector functions, promotion of survival, rescue from exhaustion and/or anergy of T cells, or a combination thereof. Chaperon-antigens can also be used to induce tolerance and increase immune suppressive responses. In the most preferred embodiments, the peptide antigen is fused to the chaperone protein to form a fusion protein. The &#34;chaperone-antigen&#34; can be combined with an adjuvant to form a vaccine and administered to a subject to modulate an immune response to the antigen. Methods of increasing immune responses, treating cancer and infectious diseases and inducing tolerance are also provided.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a composite sheet which can reduce waste liquid and absorb liquid to give a wiping member, scarcely falls off fibers of the wiping member when used and has a good handleability, to provide the wiping member using the composite sheet, and to provide a make-up member using the composite sheet.  &lt;P&gt;SOLUTION: (1) This composite sheet having a regenerated cellulose filament nonwoven fabric and a synthetic fiber fabric contains the regenerated cellulose filament nonwoven fabric in an amount of 10 to 50 wt.% and has a water retention rate of 15 to 40 wt.%. At least one side of the composite sheet is mainly formed from the regenerated cellulose filament nonwoven fabric. (2) The composite sheet whose wet bending resistance is 15 to 50%. (3) The composite sheet wherein the water retention of the synthetic fiber fabric is ≤10 wt.%. (4) The wiping member is made by impregnating the composite sheet with water or both water and a disinfectant and then sterilizing the treated composite sheet. (5) The make-up member made by impregnating the composite sheet with at least water for make-up.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
&lt;P&gt;PROBLEM TO BE SOLVED: To offer a sports electronic training system and applications thereof.  &lt;P&gt;SOLUTION: A sports electronic training system and applications thereof, are disclosed. In an embodiment, the system 100 comprises at least one monitor 104, 106 and a portable electronic processing device 102, 110 for receiving data from the at least one monitor and providing feedback to an individual 101 based on the received data. The monitor can be a motion monitor 104 that measures an individual&#39;s performance such as, for example, speed, pace and distance for a runner. Other monitors might include a heart rate monitor 106, a temperature monitor, an altimeter, et cetera. Feedback provided to a user typically includes, for example, training information such as whether the user is satisfying specific workout and/or training criteria.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
PURPOSE:To prepare a curable compsn. which cures rapidly, is excellent in curability and discoloration resistance, and forms, when cured, a slippery surface by compounding a specific polymerizable monomer with a volatile compd. and a polymn. initiator. CONSTITUTION:100pts.wt. at least one polymerizable monomer selected from the group consisting of polymers of formulas I, II, and III (wherein n is 0-3; R is H or methyl; R&#39; is a group of formula IV or V; and R&#39;&#39; is a group of formula V), 20-400pts.wt. volatile compd., and a polymn. initiator in an amt. of 0.1-10wt.% of the sum of the polymerizable monomer and volatile compd. are compounded to give the title compsn. which cures rapidly even in the presence of oxygen to form a slippery surface, is excellent in hardness and discoloration resistance, and can be widely used in industry as a surface lubricant, exhibiting an esp. excellent effect in dental fields.
Patient identification is transmitted to a health care provider prior to the patient arriving at the health care provider. The patient identification may be a driver&#39;s license, health insurance card, or other identification, and may be used to pre-register the patient. The transmission may include other information, such as health status, purpose of visit, intended procedures, symptoms, or other information. The transmission may be made via a device, such as a cellular telephone, where the information may be encrypted and transmitted using a secure mechanism. The system may be used by ambulance personnel, paramedics, or other emergency responders to notify a hospital, for example, of an inbound patient, as well as by patients prior to an appointment. The system may also be used by clinicians or other health care providers to prepare for emergent or non-emergent patients prior to arrival.
1. Use of methoxymorpholino doxorubicin (MNmX) of formula in the preparation of a medicament formulated for intrahepatic administration through hepatic artery in the treatment of a human liver tumor. 2. Use according to claim 1, wherein the liver tumor is a tumor primarily confined to the liver. 3. Use according to claim 2, wherein the tumor primarily confined to the liver is a hepatocellular carcinoma (HCC) or a cholangiocarcinoma. 4. Use according to claim 1, wherein the tumor is a liver metastasis. 5. Use according to any one of the preceding claims, wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks. 6. Use according to any of claims 1-4, wherein MMDX is administered as a 5-10 minute bolus every 8 weeks. 7. Use according to any one of the preceding claims, wherein MMDX is administered with an agent, which remains selectively in a liver tumor after its injection through the hepatic artery. 8. Use according to claim 7, wherein the agent is iodized oil. 9. Use according to any of the preceding claims, wherein MMDX is administered in a dose ranging from about 100 mcg/m&lt;2&gt; to about 1000 mcg/m&lt;2&gt;. 10. Use according to claim 9, wherein MMDX is administered in a dose ranging from about 100 mcg/m&lt;2&gt; to about 800 mcg/m&lt;2&gt;. 11. Use according to claim 11, wherein the dose is 200 mcg/m&lt;2&gt;. 12. A pharmaceutical composition, which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery. 13. Use according to claim 12, wherein the agent is iodized oil. 14. Use of a pharmaceutical composition according to claim 12 or 13 for the treatment of a liver tumor. 15. Use of a pharmaceutical composition, which comprises as an active principle MMDX and a pharmaceutically acceptable agent that remains selectively in a liver tumor after its injection through the hepatic artery, for the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumor. 16. A pharmaceutical composition according to claim 13, wherein the agent is iodized oil.
The invention discloses a preparation method for a stem cell preparation capable of preventing and treating mycoplasma pneumoniae of swine. The preparation method comprises the steps of separating swine bone marrow mesenchymal stem cells from newborn swine leg bone marrows; separating a subtype cell BMSC-S3 cell line of the swine bone marrow mesenchymal stem cells; establishing a BMSC-S3/PBD-1 cell line stably transfected by PBD-1 gene; detecting genes expressed by BMSC-S3/PBD-1 cells by using PCR; and detecting antigen molecules expressed by the BMSC-S3/PBD-1 cells by using cellular immunofluorescence chemical analysis and flow cytometry. The BMSC-S3/PBD-1 cells prepared by the method can stably express PDB-1 and has the characteristics of standard BMSC stem cells. The BMSC-S3/PBD-1 cells stably transfected by the PBD-1 gene are injected into a swine body suffering from mycoplasma pneumoniae, with an effective dosage of 1-5*10&lt;5&gt; per time per kg of weight, so that mycoplasma pneumoniae diseases of the swine can be controlled. The BMSC-S3/PBD-1 cells can be stored in a liquid nitrogen container for a long time, so that sources can be guaranteed. The stem cell preparation provided by the invention has no drug resistance; and foreign protein is processed only by the swine body, without risk of drug residues, so that the stem cell protein has wide application prospects.
PROBLEM TO BE SOLVED: To provide a safe and readily ingestible IgE antibody-suppressing agent or food capable of suppressing an IgE antibody value in vivo, preventing onset of allergic diseases such as atopic dermatitis, bronchitis and allergic rhinitis and improving a clinical picture even when these diseases are affected. SOLUTION: This IgE antibody-suppressing agent comprises glucomannan. Preferably the glucomannan has a shape of refined flour of devil&#39;s tongue and &gt;=95% dietary fiber content and the glucomannan is readily water-soluble. Preferably, the glucomannan is subjected to powering treatment in order to make the glucomannan readily water-soluble. Preferably the powered glucomannan has &gt;=1,000,000 weight average molecular weight and &lt;=100 μm average particle diameter and a time required for 1% aqueous solution at room temperature to attain viscosity peak is within 30 min. The IgE antibody-suppressing agent has a form of powder, capsule, tablet, pill or granule.
PROBLEM TO BE SOLVED: To obtain a natural killer(NK) cell activation agent that is safe and shows the NK cell activation action, when it is orally given to human without toxicity to human and is useful as a material for physiologically functional foods. SOLUTION: This NK cell activation agent includes an oligoglucosamin as an active ingredient. The activation agent is preferably prepared as an oral administration product. In a preferred embodiment, this oligoglucosamine is obtained by hydrolyzing chitosan with chitosanase. In addition, it is preferable that the oligoglucosamin usually includes the trimer to hexamer of glucosamin in an amount of &gt;=50 wt.%, particularly &gt;=70 wt.% based on the whole glucosamins. The content of the oligoglucosamin is usually &gt;=0.1 wt.%, when it is added to foods and is usually &gt;=10 wt.%, when it is used as an oral oligoglucosamin preparation, or the like.
The present invention relates to a natural complex antiseptic composition containing Tabebuia avellanedae, Smilax glabra, Agastache rugosa (Fisch. &amp;amp; Mey.) Kuntze, and Rumex japonicus HOUTT. extracts. The natural complex antiseptic composition of the present invention has superior antiseptic and antibacterial effects without toxicity to a human body, thereby being used as a natural antiseptic of cosmetic products, foods, and medicinal products instead of a synthetic antiseptic. [Reference numerals] (AA) Fungal species;(BB) Experimental group average;(CC) Test example 6
A complex of an anionic polysaccharide with silver. The complex is preferably a salt formed between the polysaccharide and Ag&lt;+&gt; and the anionic polysaccharide is preferably a polycarboxlate. The anionic polysaccharide may be selected from alginates, hyaluronates, pectins, carageenans, xanthan gums, sulfated dextrans, cellulose derivatives, oxidised celluloses and mixtures thereof. Also claimed is a wound dressing, such as a sponge sheet, a woven or non-woven fabric, or a gel sheet, comprising a complex of an anionic polysaccharide with silver for treating ulcers. The wound dressing may further comprise collagen and preferably also comprises oxidised regenerated cellulose. Also claimed is the use of the aforementioned complex for the preparation of a medicament for the treatment of wounds and a method of making the complex comprising the step of treating an anionic polysaccharide with a solution of a silver salt.
The invention belongs to the field of traditional Chinese medicine preparation and particularly relates to a plaster for treating bone injuries and a preparing method thereof. The plaster is prepared from a traditional Chinese medicine coarse material, a traditional Chinese medicine fine material, vegetable oil and yellow lead according to weight parts. The plaster and the method are advantageous in that traditional Chinese medicines used in the plaster meet regulations of the &#39;Pharmacopoeia of China&#39; and are safe and reliable. The medicines are compatible and have functions of activating blood circulation to remove stasis, relieving swelling, arresting pain, relaxing muscles and tendons, regulating qi, dispelling wind and cold and promoting reunion of the fractured bones. The plaster has the characteristics of definite curative effects, rapid production of desired effects, a high curative rate, no side effects, and the like when the plaster is used for treating the bone injuries. The plaster is mainly used for treating (1) bone and joint organic lesions of various types, such as various types of arthritis, periarthritis humeroscapularis, cervical spondylosis, osteoproliferation and bony spurs, (2) various traumatic skin, bone, tendon and vessel lesions, such as various types of traumatic injuries, fracture, and tendon and vessel contracture, and (3) muscle strain lesions of various parts, such as soreness of waist, backache, and neck and shoulder (muscle) pain.
PROBLEM TO BE SOLVED: To obtain a melanin formation inhibitor capable of preventing pigmen tation of the skin and a dermal preparation for external use having excellent whitening effect. SOLUTION: This melanin formation inhibitor contains a borneol-p- hydroxycinnamate glycodise expressed by the formula (R is a monosaccharide residue, a disaccharide residue or a trisaccharide residue). At least one kind of the melanin formation inhibitor in an amount of 0.05-10wt.%, preferably 0.1-5wt.% based on whole preparation is contained in the dermal preparation for external use as an active component. The compound of the formula has suppressing action on the formation of melanin, a suppressing action on pigmentation after irradiat with ultraviolet rays and an ultraviolet rays-protecting action.  The compound is mixed to a based excipient of the dermal preparation for external use to obtain a composition which has an excellent whitening effect on the skin and is effective to prevent and cure a local chromatosis such as spots, freckles or a blackening by sunburn, or a systemic chromato a is such as Addison&#39;s disease. The composition is also excellent in safety and stability and capable of continuously using for a long period of time.
A system and method of providing information concerning pathological findings evidenced by radiographical reports. A medical care provider may request a radiographical image, in particular, an MRI image of a region of the body. The region of the patient&#39;s body is scanned and the images are read and interpreted to determine if there is a positive finding of a pathology. If a pathology is detected, the generated scanned images are reviewed for a radiographical image that best depicts the detected pathology and the image is selected for further annotation. The image is then annotated to highlight and more fully describe and delineate the pathology thus alerting the medical care provider of the pathology&#39;s existence. In addition, the report may be further delineated with an identifying mark informing the referring physician of a positive finding of a pathology.
PURPOSE:To obtain the subject tablet controlling the release of a medicine by blending a specified amount of water-soluble polymer and water-insoluble polymer and coating the blended polymer mixture to a constant thickness. CONSTITUTION:A composition obtained by blending a water soluble polymer (e.g. polyethylene glycol) with a water-insoluble polymer (e.g. ethylcellulose) in an amount of equivalent-3 times weight based on the former polymer is coated. Coating is carried out in a solvent such as ethanol at 40-70 deg.C using a spray coater so that the coating thickness may be 100-1000mum. The coated material is subjected to preparation into a tablet, thus obtaining the objective material. As for the strength of the tablet, the wet strength directly after 12hr&#39; dissolution test is preferably &gt;=0.2kg and releasing time of the medicine is preferably 4-18hr. The resultant tablet has a high strength enough to resist against mechanical stress due to motions, etc., of the digestive tube and can be applied for a sustainingly releasable fertilizer, agricultural chemical, bath agent, etc.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide a control technology for making an optical reflection effect and transmission effect suitable for cosmetic purposes.  &lt;P&gt;SOLUTION: The powder is obtained by coating the surface of barium sulfate with one or more kinds selected from titanium dioxide, zinc oxide, aluminum oxide, silica, zirconium oxide, iron oxide and compounded products thereof. The skin external preparation comprises the composite powder. Preferably the barium sulfate has a plate-like shape. The metal oxides and the compound oxides are preferably in a fine particle form.  &lt;P&gt;COPYRIGHT: (C)2010,JPO&amp;INPIT
A new method to capture, purify and expand antigen-specific T lymphocites has been developed using magnetic beads coated with recombinant MHC class I molecules. This method was optimized using homogenous populations of naive T cells purified from mice transgenic for the 2C T cell receptor (TCR). These T cells were captured on beads coated with MHC class I molecules and the relevant antigenic peptides. MHC and peptide specificity was confirmed by the usage of irrelevant MHC peptide combinations. An enrichment of 800 to 1600 fold was measured, using 2C T cells mixed with irrelevant T cells, starting from a 2C T cell frequency of 1/3000. The same approach was used to purify antigen-specific CD8&lt;+&gt; T cells from total CD8&lt;+&gt; T cells from naive mice. The recovered cells could be expanded and specifically kill target cells in vitro; they had a significant effect in vivo as well. We expect this procedure to be suitable to purify and expand in vitro tumor- and virus-specific killer T cells for use in cell therapy.
The present invention is a novel thermally-responsive record material comprising a substrate having provided thereon in substantially contiguous relationship an electron donating dye precursor, an acidic developer materia l, a compound of formula (I) wherein P is selected from (II) and (III), wherein  R~1?, R~2? and R~3? are independently selected from hydrogen, alkyl, alkoxy,  aryl, aralkyl, aralkoxy, halogen, and alkoxyalkoxy; wherein R~4? is independently selected from alkoxyalkyl, alkoxyalkoxy, and aralkoxyalkoxy, a nd a suitable binder therefor. In the context of the present invention the alky l moieties in the alkyl, aralkyl, aralkoxy, alkoxyalkyl, alkoxyalkoxy and aralkoxyalkoxy preferably are eight carbons or less, and more preferably fro m one through four carbons. Substituents on aryl moieties in aryl, aralkyl, aralkoxy, and aralkoxyalkoxy groups can include hydrogen, alkyl, alkoxy and halogen. The alkyl group in these substituents also is eight carbons or less , and more preferably from one through four carbons. The thermally responsive record material of the invention has the unexpected and remarkable propertie s of enhanced image intensity or density, and/or improved thermal response.&lt;/S DOAB&gt;